Therapeutic Potential of a Polymer-Encapsulated l-DOPA and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson’s Disease
Identifieur interne : 001E50 ( Main/Exploration ); précédent : 001E49; suivant : 001E51Therapeutic Potential of a Polymer-Encapsulated l-DOPA and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson’s Disease
Auteurs : Mark D. Lindner [États-Unis] ; Dwaine F. Emerich [États-Unis]Source :
- Cell Transplantation [ 0963-6897 ] ; 1998.
English descriptors
- KwdEn :
Abstract
Encapsulation of cells within polymer membranes prior to transplantation provides a novel means of achieving continuous, site-specific delivery of therapeutic molecules to the CNS. The use of encapsulated dopamine-secreting cells that can be transplanted directly into the striatum has particular appeal for the treatment of Parkinson’s disease. This article provides a brief and timely review of the progress that has been made over the past decade using encapsulated PC12 cells as a means of delivering dopamine and l-DOPA to the striatum in rodent and primate models of Parkinson’s disease. The polymer membranes are well tolerated and biocompatible. Encapsulated PC12 cells survive in vivo for up to 6 mo, they release dopamine into the surrounding host striatum, and they clearly improve behavioral function in both dopamine-depleted rodents and primates. Although these results are promising, fundamental issues remain concerning the extent of dopamine diffusion from the polymer membranes and the number of devices needed for behavioral improvement, and the duration and consistency of cell viability and device output. Nevertheless, this technology appears to be a promising means of avoiding many of the practical, societal, and ethical issues that have been associated with other transplantation approaches.
Url:
DOI: 10.1016/S0963-6897(97)00169-3
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic Potential of a Polymer-Encapsulated l-DOPA and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson’s Disease</title><author><name sortKey="Lindner, Mark D" sort="Lindner, Mark D" uniqKey="Lindner M" first="Mark D" last="Lindner">Mark D. Lindner</name></author><author><name sortKey="Emerich, Dwaine F" sort="Emerich, Dwaine F" uniqKey="Emerich D" first="Dwaine F" last="Emerich">Dwaine F. Emerich</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A632BE0E80A18D147C1960D1A41E82480ABEB39C</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1016/S0963-6897(97)00169-3</idno><idno type="url">https://api.istex.fr/document/A632BE0E80A18D147C1960D1A41E82480ABEB39C/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002096</idno><idno type="wicri:Area/Main/Curation">001D95</idno><idno type="wicri:Area/Main/Exploration">001E50</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Therapeutic Potential of a Polymer-Encapsulated l-DOPA and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson’s Disease</title><author><name sortKey="Lindner, Mark D" sort="Lindner, Mark D" uniqKey="Lindner M" first="Mark D" last="Lindner">Mark D. Lindner</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>CytoTherapeutics Inc., Lincoln, RI 02865</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="Emerich, Dwaine F" sort="Emerich, Dwaine F" uniqKey="Emerich D" first="Dwaine F" last="Emerich">Dwaine F. Emerich</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Alkermes Inc., Cambridge, MA 02139</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Cell Transplantation</title><title level="j" type="abbrev">CTR</title><idno type="ISSN">0963-6897</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1998">1998</date><biblScope unit="volume">7</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="165">165</biblScope><biblScope unit="page" to="174">174</biblScope></imprint><idno type="ISSN">0963-6897</idno></series><idno type="istex">A632BE0E80A18D147C1960D1A41E82480ABEB39C</idno><idno type="DOI">10.1016/S0963-6897(97)00169-3</idno><idno type="PII">S0963-6897(97)00169-3</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0963-6897</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal models</term><term>Cell line</term><term>Encapsulation technology</term><term>Parkinson’s disease</term><term>Potential efficacy</term><term>Transplantation</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Encapsulation of cells within polymer membranes prior to transplantation provides a novel means of achieving continuous, site-specific delivery of therapeutic molecules to the CNS. The use of encapsulated dopamine-secreting cells that can be transplanted directly into the striatum has particular appeal for the treatment of Parkinson’s disease. This article provides a brief and timely review of the progress that has been made over the past decade using encapsulated PC12 cells as a means of delivering dopamine and l-DOPA to the striatum in rodent and primate models of Parkinson’s disease. The polymer membranes are well tolerated and biocompatible. Encapsulated PC12 cells survive in vivo for up to 6 mo, they release dopamine into the surrounding host striatum, and they clearly improve behavioral function in both dopamine-depleted rodents and primates. Although these results are promising, fundamental issues remain concerning the extent of dopamine diffusion from the polymer membranes and the number of devices needed for behavioral improvement, and the duration and consistency of cell viability and device output. Nevertheless, this technology appears to be a promising means of avoiding many of the practical, societal, and ethical issues that have been associated with other transplantation approaches.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Massachusetts</li><li>Rhode Island</li></region></list><tree><country name="États-Unis"><region name="Rhode Island"><name sortKey="Lindner, Mark D" sort="Lindner, Mark D" uniqKey="Lindner M" first="Mark D" last="Lindner">Mark D. Lindner</name></region><name sortKey="Emerich, Dwaine F" sort="Emerich, Dwaine F" uniqKey="Emerich D" first="Dwaine F" last="Emerich">Dwaine F. Emerich</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E50 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001E50 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A632BE0E80A18D147C1960D1A41E82480ABEB39C
|texte= Therapeutic Potential of a Polymer-Encapsulated l-DOPA and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson’s Disease
}}
| This area was generated with Dilib version V0.6.23. |  |